10q10k10q10k.net

vs

Side-by-side financial comparison of PRECISION BIOSCIENCES INC (DTIL) and 10x Genomics, Inc. (TXG), based on the latest 10-Q / 10-K filings. Click either name above to swap in a different company.

Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.

10x Genomics, Inc. is an American biotechnology company that designs and manufactures gene sequencing technology used in scientific research. It was founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin Ness.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history — bar widths are scaled to the larger of the two companies so you can eyeball the size gap and growth trajectory without doing math. Quarters aligned by calendar period (report date) so offset fiscal years line up.

Revenue
DTIL
DTIL
TXG
TXG
Q4 25
$34.2M
Q3 25
$13.0K
Q2 25
$18.0K
Q1 25
$29.0K
Q4 24
$638.0K
Q3 24
$576.0K
Q2 24
$49.9M
Q1 24
$17.6M
Net Profit
DTIL
DTIL
TXG
TXG
Q4 25
$20.1M
Q3 25
$-21.8M
Q2 25
$-23.5M
Q1 25
$-20.6M
Q4 24
$-17.7M
Q3 24
$-16.4M
Q2 24
$32.7M
Q1 24
$8.6M
Operating Margin
DTIL
DTIL
TXG
TXG
Q4 25
36.6%
Q3 25
-158976.9%
Q2 25
-121538.9%
Q1 25
-76248.3%
Q4 24
-3894.4%
Q3 24
-3693.6%
Q2 24
48.4%
Q1 24
-23.8%
Net Margin
DTIL
DTIL
TXG
TXG
Q4 25
58.9%
Q3 25
-167476.9%
Q2 25
-130666.7%
Q1 25
-70913.8%
Q4 24
-2781.3%
Q3 24
-2851.6%
Q2 24
65.6%
Q1 24
48.8%
EPS (diluted)
DTIL
DTIL
TXG
TXG
Q4 25
$2.62
Q3 25
$-1.84
Q2 25
$-2.13
Q1 25
$-2.21
Q4 24
$-3.08
Q3 24
$-2.25
Q2 24
$4.67
Q1 24
$1.70

Financial Flow Comparison

Sankey diagram of revenue → gross profit → operating profit → net profit for each company. Charts shown full-width and stacked so both segment hierarchies are readable side-by-side on desktop and mobile.

Related Comparisons